INNOVENT BIO (01801): Sintilimab ZYBRIVO receives positive CHMP opinion recommending approval for first-line treatment of non-squamous non-small cell lung cancer
Innovent Biologics (01801) announced that sintilimab (European trade name: Zybrivo) has received the first positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP recommends approval of the marketing authorization for sintilimab in combination with chemotherapy for the treatment of adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo will expand first-line treatment options for lung cancer patients in Europe. Sintilimab is an immunotherapy drug and a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1).
INNOVENT BIO (01801) announced that sintilimab (European trade name: Zybrivo) has received the first positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), with the CHMP recommending approval of the marketing authorization for sintilimab in combination with chemotherapy for the treatment of adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo will expand first-line treatment options for lung cancer patients in Europe. Sintilimab is an immunotherapy drug and a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1).
The CHMP recommendation is based on results from the Phase III ORIENT-11 study (NCT03607539). This was a randomized, multicenter, double-blind, placebo-controlled Phase III study that enrolled a total of 397 adult patients with locally advanced, metastatic or recurrent non-squamous NSCLC without EGFR or ALK genomic tumor aberrations, regardless of PD-L1 expression level. Patients were randomized 2:1 to receive sintilimab or placebo, both in combination with pemetrexed and platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS) as assessed by the blinded independent radiological review committee.
In the ORIENT-11 study, compared with placebo plus chemotherapy, sintilimab plus chemotherapy reduced the risk of disease progression or death by 52% (median PFS: 8.9 months vs. 5.0 months) and reduced the risk of death by 35% (median overall survival (OS): 24.2 months vs. 16.8 months). The study results demonstrated the clinical benefit of sintilimab plus chemotherapy and its potential to provide an additional first-line treatment option for eligible patients with advanced non-squamous NSCLC in Europe. The safety profile of sintilimab plus chemotherapy was consistent with the known safety profiles of PD-1 inhibitors and the chemotherapy agents used, with no new safety signals identified.
The indication recommended for approval by the CHMP this time is: Zybrivo in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with non-squamous NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and who meet the following conditions: locally advanced NSCLC that is not amenable to curative surgery or chemoradiation; or metastatic NSCLC.
The company's mission is to develop high-quality biopharmaceuticals that are affordable. The positive CHMP opinion for sintilimab is an important regulatory milestone in the company's international development process and brings the company one step closer to serving patients in Europe. The ORIENT-11 study confirmed the clear clinical benefit of sintilimab, and if approved, this drug will add a new treatment option for patients with non-squamous non-small cell lung cancer in Europe. At the same time, the company is strengthening its capabilities to support patient access to the product in major European markets. The company will continue to advance the development of innovative therapies and strive to bring more valuable therapeutic drugs to patients worldwide.
Following the positive CHMP opinion, the European Commission is expected to make a final decision on the marketing authorization in the coming months. If approved, the authorization will be valid in all 27 EU member states as well as Iceland, Norway and Liechtenstein.
Related Articles

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.

Guangdong Shenling Environmental Systems (301018.SZ) plans to participate in bidding for land use rights to meet its development needs in the liquid cooling and temperature control field.

U.S. "Vulcan" rocket launch fails, 40 Amazon.com, Inc. (AMZN.US) satellites destroyed, broadband network deployment faces obstacles.
BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.

Guangdong Shenling Environmental Systems (301018.SZ) plans to participate in bidding for land use rights to meet its development needs in the liquid cooling and temperature control field.

U.S. "Vulcan" rocket launch fails, 40 Amazon.com, Inc. (AMZN.US) satellites destroyed, broadband network deployment faces obstacles.






